Cigna (CI) Stock Forecast & Price Target

Cigna Group is strategically positioned to capitalize on the growing biosimilars market, expected to reach $100 billion by 2030, enhancing its revenue potential in the pharmaceutical sector. The company is also projected to provide double-digit savings on GLP-1 net cost development for its employer clients, further strengthening its value proposition for self-funded health insurance plans. Additionally, Cigna's Evernorth build-out is anticipated to provide economic resilience, helping to offset potential earnings headwinds during a recession while maintaining a focus on driving lower net costs.

Cigna Group faces significant risks that could negatively impact its financial outlook, including challenges in accurately pricing healthcare costs and ongoing regulatory scrutiny of its pharmacy benefit management services. The company may experience slower adoption of biosimilars and a lack of specialty drug penetration, which could hinder growth in its Evernorth segment, compounded by potential client losses. Furthermore, rising unemployment may adversely affect Cigna’s commercial membership, further straining its financial performance in a competitive environment.